EUVIMEDEUVIMED entdecken
Crossref

The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?

Annette E Bowyer iD, Rhona M Maclean, Steve Kitchen iD

International Journal of Laboratory Hematology · 2023

DOI: 10.1111/ijlh.14021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2023. Verfasst von Annette E Bowyer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Coagulation, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The bispecific antibody, emicizumab, is a prophylactic therapy used for the treatment of haemophilia A (HA). Patients may require additional replacement factor VIII (FVIII) to ensure adequate haemostasis. This study investigated the laboratory measurement of severe HA (SHA) plasma spiked with 36 combinations of emicizumab plus recombinant (r) FVIII concentrates.

Method

FVIII assays were performed by one stage assay (OSA) using eight APTT reagents from three manufacturers and chromogenic assays (CSA) using seven kits. CSA kits comprised a range of bovine FX/FIXa, bovine FX/human FIXa or human FX/FIXa. Thrombin generation (TG) was assessed by CAT and ST‐Genesia.

Results

Emicizumab‐calibrated modified OSA and human FX CSA both overestimated rFVIII in the presence of emicizumab; median FVIII:C of up to 89% higher was observed in plasma spiked with both drugs compared to just rFVIII. In bovine FX CSA assays, there was a FVIII:C increase of up to 11% in plasmas spiked with both drugs compared to rFVIII alone. TG parameters were not all normalized by the presence of emicizumab however addition of rFVIII increased TG. ETP and peak thrombin were normalized at 50 μg/ml emicizumab using ST‐Genesia but were still reduced at 75 μg/ml with CAT. Addition of rFVIII further normalized results.

Conclusion

Modified OSA and human FX CSA could not distinguish between rFVIII or emicizumab. The presence of both emicizumab and rFVIII increased thrombin generation to normal levels compared to each drug alone. Bovine FX CSA can be used to accurately determine FVIII activity of rFVIII in plasma which also contains emicizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemostaticsAnimalsCattleHumansFactor VIIIThrombinAntibodies, BispecificAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

chromogenicemicizumabhaemophiliaone-stagerecombinant FVIII

Substanzen

Factor VIIIHemostaticsThrombinemicizumabAntibodies, BispecificAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Coagulation, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.

ORCID-Profile: Annette E Bowyer, Steve Kitchen

Förderung

  • Roche

Zitieren

APA

Bowyer, A. E., Maclean, R. M., & Kitchen, S. (2023). The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14021

Vancouver

Bowyer AE, Maclean RM, Kitchen S. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?. International Journal of Laboratory Hematology. 2023. doi:10.1111/ijlh.14021

BibTeX
@article{Bowyer2023,
  author = {Bowyer, Annette E and Maclean, Rhona M and Kitchen, Steve},
  title = {The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?},
  journal = {International Journal of Laboratory Hematology},
  year = {2023},
  doi = {10.1111/ijlh.14021}
}
Kostenlos starten →